Genentech - fly Baby fly

www.quote.com/quotecom/livecharts/default.asp?symbols=DNA

"The introduction of TNKase has the potential to significantly impact how heart attack patients are now treated due to the speed and ease with which it can be administered," said Christopher Granger, MD, FACC, associate professor of medicine and director of the cardiac care unit at Duke University Medical Center in Durham, NC, and lead U.S. investigator for ASSENT 2.

ASSENT 2 yielded the following mortality rates: TNKase (Tenecteplase), 6.2
percent (n=8461); Activasee (Alteplase, recombinant), 6.2 percent (n=8488).
There were similar rates for intracranial hemorrhage (Activase, 0.9 percent;
TNKase, 0.9 percent) and stroke (Activase, 1.7 percent; TNKase, 1.8 percent). In addition, non-intracranial major bleeding and the need for blood transfusions were lower in patients treated with TNKase compared to Activase. As with all thrombolytics, the most significant adverse events observed in clinical trials with TNKase included intracranial hemorrhage and stroke.

"Rapid treatment is critical to most effectively manage patients with heart
attacks," said Dr. Granger. "The ability to treat patients rapidly depends on having simple treatments available which can be given easily in busy emergency departments."

About TNKase for Acute Myocardial Infarction

Genentech's leadership in cardiovascular medicine and in the development of
thrombolytic therapy helped revolutionize heart attack treatment more than a
decade ago. A bioengineered plasminogen activator, TNKase is similar to
Activase, which is a recombinant DNA-derived version of naturally-occurring
tissue plasminogen activator (t-PA). TNKase has unique features specifically
designed to prolong its half life, enabling single bolus dosing. It also has
been designed to increase specificity for fibrin, a key component of
intracoronary clots and results in less disturbance of the body`s coagulation, or natural clotting, system.

TNKase (Tenecteplase) is currently under investigation in four ongoing clinical studies that began early this year, involving more than 9,000 patients, to evaluate various heart attack regimens in combination with other agents.

In addition to its clinical features, TNKase will be provided to the medical
community as part of a kit which will include a needleless injection system, the first thrombolytic to be packaged with this device. This system is designed to comply with new OSHA (Occupational Safety and Health Administration) directives to protect health care workers.

Heart attack strikes more than 1.1 million people in the United States and
causes nearly 500,000 deaths each year. Therapies and procedures that open the blocked artery causing the heart attack have been shown to significantly improve survival, but they must be administered within a few short hours of the onset of symptoms, which include chest pain or discomfort, difficulty breathing, "cold sweats," and nausea.

TNKase currently is under regulatory review by the European Regulatory Authority for the treatment of heart attack. Upon approval, TNKase will be marketed in Europe by Genentech's international marketing partner, Boehringer Ingelheim.

Genentech, Inc. is a leading biotechnology company that discovers, develops,
manufactures and markets human pharmaceuticals for significant unmet medical
needs. Fourteen of the approved products of biotechnology stem from Genentech
science. Genentech markets eight products directly in the United States. The
company has headquarters in South San Francisco, California, and is traded on the New York Stock Exchange under the symbol DNA.

For TNKase and Activase full prescribing information, please call 650-225-7848
or contact Genentech at www.gene.com.

((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at www.presswire.net on the world wide web.
Inquiries to info@m2.com)).

-0-

(C)1994-2000 M2 COMMUNICATIONS LTD

nachdem die Dinger heute über 19 $ in die Höhe geschossen sind,müßte sich das doch auch auf die BB Biotech Aktie auswirken.

Ich selbst habe für meine Verhältnisse sehr viele BB Bios im Depot (knapp 10% Depotanteil).

Habe mittlerweile kein gutes Gefühl mehr dabei - BB Bio kommt nicht von der Stelle, obwohl auch Immunex und vor allem Medimmune eine sehr gute Performance gezeigt haben.
Vor ein paar Tagen wurde hier ein kritischer Artikel bezüglich des undurchsichtigen Firmengeflechts von BB Bio gepostet.
Vielleicht ist da ja doch was dran? Ich empfehle die Entwicklung in der nächsten Zeit sehr genau zu verfolgen - gerade unter dem Aspekt der (guten) Entwicklung der BB Bio-Depotgrößen. Wenn diese Entwicklung nicht nachvollzogen wird, steige ich aus.

Gruß
EXPRO

www.gene.com./news/2000/20000605-061754.html

Komisch, die in D gehandelten Schweizer Aktien (in ganz) zeigten heute schöne  Zuschläge, im Xetra über 12 %. Da scheint diese Verflechtungsgeschichte, die sowieso von Anfang an bekannt war, ja offensichtlich niemand zu interessieren.
Bei unseren Aktien war aber auch nix Auffälliges im Verkaufsbereich, das Handelsvol. war auch durchschnittlich. Was soll das ??

www.quicken.com/investments/quotes/?symbol=DNA&B1=Go

Nix soll das - wollte nur zu (noch) mehr Wachsamkeit aufrufen.
Mir persönlich war "die Verflechtungsgeschichte" leider nicht bekannt - und hat mich daher ein wenig beunruhigt.

BB Biotech ist jedenfalls nicht so gut gelaufen wie die oben von mir genannten Werte (ganz kurzfristig gesehen).
Vielleicht bin ich auch zu kritisch zur Zeit und meine "Sorge" verflüchtigt sich schon sehr bald.

Gruß
EXPRO